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Abstract  
 
We aimed to investigate long-term outcomes in psychotic major depression patients compared to 
schizophrenia and bipolar/manic psychosis patients, in an incidence sample, while accounting for 
diagnostic change. 
 
Based on Aetiology and Ethnicity in Schizophrenia and Other Psychoses (ÆSOP and ÆSOP-10), a first 
episode psychosis cohort was followed-up 10 years after first presentation. The Schedules for 
Clinical Assessment in Neuropsychiatry, WHO Life Chart and Global Assessment of Functioning were 
used to assess clinical, social and service use outcomes. 
 
Seventy-two PMD patients, 218 schizophrenia patients and 70 psychotic bipolar disorder / mania 
patients were identified at baseline. Differences in outcome between PMD and bipolar patients 
based on baseline and lifetime diagnosis were minimal. Differences in clinical, social and service use 
outcomes between PMD and schizophrenia were more substantial with PMD patients showing 
better outcomes on most variables. However, there was some weak evidence (albeit not quite 
statistically significant at p < 0.05) based on lifetime diagnoses that PMD patients were more likely to 
attempt suicide (OR 2.31, CI 0.98-5.42, p0.055) and self-harm (OR 2.34, CI 0.97-5.68, p0.060). 
 
PMD patients have better social and service use outcomes compared to people with schizophrenia, 
but may be more likely to attempt suicide or self-harm. This unique profile is important for clinicians 
to consider in any risk assessment.  
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1 Introduction 
Major depression with psychotic features, also known as Psychotic Major Depression (PMD), is 
defined by ICD–10 (WHO, 1993) as a depressive disorder with the addition of delusions, 
hallucinations or depressive stupor. A systematic review and meta-analysis by Kirkbride et al. (2012) 
reported a pooled incidence for PMD in England of 5.3 (95% CI 3.7-7.6) per 100,000 person years. 
This was compared with 3.7 per 100,000 person years (95% CI 3-4.5) for bipolar with psychotic 
symptoms and 15.2 per 100,000 person years (95% CI 11.9-19.5) for schizophrenia. These results 
suggest that PMD is less common than schizophrenia, but more common than bipolar disorder. 
Despite these incidence rates, PMD is a largely under-researched disorder (Crebbin et al., 2008). 
 
Many studies have investigated the long-term course of illness and outcomes in psychosis (Ciopmi, 
1980; Harrison et al., 2001; Hill et al., 2012; Takei et al., 1998). However, studies have less often 
included outcomes on PMD patients (Ciccone & Racy, 1975; Schimmelmann et al., 2005; DelBello et 
al., 2003; Bromet et al., 1996) and importantly, few have compared outcomes in people with PMD to 
outcomes in other major psychotic diagnostic groups such as schizophrenia and bipolar patients. 
Further, many studies which include outcomes for PMD are based on prevalence samples or samples 
of only inpatients, both of which are biased towards those with longer duration and more severe 
illness (Cohen & Cohen, 1984) and consequently may give a distorted picture of long-term prognosis. 
 
The four studies which have to date examined outcomes in PMD patients in incidence samples 
(Crebbin et al., 2008; Amin et al., 1999; Baldwin et al., 2005; Whitty et al., 2005) were conducted 
over a relatively short period of time (6 months – 4 years); therefore, knowledge of longer-term 
outcomes is limited. While, three of these studies examined diagnostic stability only (Amin et al., 
1999; Baldwin et al., 2005; Whitty et al., 2005). Crebbin et al. (2008) also reported some clinical and 
service use outcomes. They found that there was a similar percentage of deaths in the year after 
first presentation in the people with PMD (9.5%, n10/105) and schizophrenia (9.6%; n7/73). They 
also reported no difference in number of admissions or admission days between those with PMD 
and those with schizophrenia, but more use of compulsory admissions in schizophrenia patients. 
Although the authors state that diagnosis was stable in PMD at 87%, this is contrary to findings in 
other studies (65% (Amin et al., 1999), 73% (Whitty et al., 2005), <50% (Heslin et al. 2015)). Based on 
these studies, accounting for diagnostic stability is important for outcome research in PMD patients 
who change diagnosis may have different outcomes compared to those who start with that 
diagnosis and retain it over time. 
 
1.1 Aims of the Study 
Given the paucity of information on long-term outcomes for PMD patients in less biased samples, we 
aimed to examine long term (10 year) outcomes in people with PMD, while improving on the 
methodological limitations of previous research by studying an incidence sample (the ÆSOP study), 
and accounting for diagnostic change. Outcomes in people with PMD were compared to outcomes 
for schizophrenia and bipolar / manic psychosis patients. Specifically, we chose to investigate the 
following aspects of outcome in PMD patients: clinical outcomes (symptoms, course of illness, 
suicide attempts and self-harm); social outcomes (disability, employment, relationship status, close 
confidants and time in prison); and service use outcomes (days hospitalised and compulsory 
admissions).  
  
2 Methods 
This paper is based on the ÆSOP-10 study which is fully described in Morgan et al. (2014) In brief, 
ÆSOP-10 is a 10 year follow-up of a cohort of people with a first episode of psychosis. The original 
cohort was identified from all inpatient and outpatient mental health services in two well defined 
catchment areas in the UK (Kirkbride et al., 2006). At baseline, detailed information was collected to 
enable re-contact for all patients. We aimed to trace, re-contact and re-interview all patients at 
approximately 10 years. Patients were contacted via current mental health services, if in contact 
with services, by inviting them to participate through their clinical teams. For those not in contact 
with services, letters were sent to their last known address inviting them to participate. Non-
responders were sent a further letter two weeks later with a maximum of three visits to the address 
if needed to make initial contact. For those believed to have moved address, we sought to make 
contact and invite them to participate through their GP if known.  
 
2.1 Measures 
At baseline, data on demographics (age, gender, ethnicity, centre, place of birth) were collected 
using the Medical Research Council Socio-demographic Schedule (Mallett, 1997). The Schedules for 
Clinical Assessment in Neuropsychiatry (SCAN version 2 (WHO, 1994)) was used to elicit symptom-
related data at the time of presentation. Symptom data plus all available clinical information 
(excluding diagnosis) was used to assign ICD-10 (WHO, 1993) psychotic diagnoses within consensus 
meetings involving the research team. These meetings involved at least one senior psychiatrist. 
Diagnosis was made as soon as possible after first contact (generally within a few weeks). Diagnoses 
were made blind to ethnicity and diagnosis from the clinical notes. 
 
A range of measures were used to collect data at follow-up. Relevant to this paper are the SCAN, the 
WHO Life Chart and the Global Assessment of Functioning (GAF). The SCAN was repeated where 
interview with patients were possible, and completed in relation to the preceding month. An 
extended version (detailed in Morgan et al. (2014)) of the WHO Life Chart (Harrison et al., 2001; 
Sartorius, et al., 1996; Burns et al., 1999) was completed for each patient using where possible, 
clinical interviews with patients and information from treating clinicians plus clinical notes, to map 
course of illness and symptom history. The Life Chart collates information on course of illness and 
three key areas of outcome: clinical; social; and service use. Items from the Life Chart relevant to this 
paper were: course of illness (episodic, continuous or neither); occurrence of suicide attempts and 
self-harm; relationship status, employment status, presence of a close confidant and whether the 
person spent any follow-up time in prison; and number of days as an inpatient and ever compulsorily 
admitted. Suicide attempts were defined as a deliberate act of self-harm with the intention of 
ending one’s life. If there was any doubt about the intention, then it was rated as self-harm. Self-
harm was defined as intentional injury to one’s body. If there was any doubt about whether 
something was deliberate, it was not counted. The split GAF was used to characterise overall 
symptomatology and function in the month prior to follow-up (Harrison et al., 2001, adapted from 
Endicott et al., 1976) based on presentation at follow-up: the GAF symptom scale; and the GAF 
disability scale. Higher GAF scores indicate fewer symptoms or a better level of functioning. 
Information from the SCAN at follow-up and Life Chart were used to determine lifetime diagnosis 
using the consensus approach as at baseline, and blind to ethnicity and baseline diagnosis. 
 
2.2 Ethics 
Full ethical approval for all aspects of the follow-up was provided by the local research ethics 
committees in South East London and Nottingham. All researchers had substantive or honorary 
contracts with either the South London and Maudsley National Health Service (NHS) Foundation 
Trust or the Nottingham Healthcare NHS Trust, the primary participating service providers. 
 
2.3 Analyses 
All data were analysed using STATA (version 11; StataCorp, 2009). Data were described using means 
and standard deviations, medians and interquartile ranges or frequencies and percentages as 
appropriate. Outcomes for PMD patients were compared with outcomes for bipolar disorder and 
schizophrenia patients. Categorical outcomes were analysed using logistic regression. Continuous 
outcomes were analysed using bootstrap regression (1000 replications) to account for the skewed 
nature of the data (Kielhorn & Graf von Schulenberg, 2000). Bootstrap regression analyses produce 
the same coefficients are interpreted in the same way as linear regressions but produce more robust 
confidence intervals. 
  
3 Results 
A total of 557 first episode patients were identified at baseline. Data presented here are based on 
the incidence sample (n, 505) collected over the first 2 years (excluding: non-incidence patients 
collected for the brain imaging component of the study; patients oversampled in the 3rd year in 
order to increase the numbers for the ethnicity component of the study; and patients excluded post 
baseline). Data presented here are for the PMD, schizophrenia and bipolar disorder / mania patients 
only (n360) (i.e., excluding delusional disorder, schizoaffective disorder, acute & transient psychoses, 
drug induced psychoses and psychoses NOS). 
 
3.1 Sample characteristics 
Of the 360 patients included here, 72 had a baseline diagnosis of PMD, 218 had a diagnosis of 
schizophrenia, and 70 had a diagnosis of bipolar disorder or mania with psychotic symptoms at 
baseline. Table 1 describes the demographics of these three groups and the sample overall. Of the 
360 patients of interest, 24 patients had died and 23 patients had moved abroad. Two hundred and 
sixty eight had some follow-up data at 8-12 years (54 PMD patients, 161 schizophrenia patients and 
53 bipolar/mania patients). Therefore only 45 patients were lost to follow-up (12.5%). Differences in 
the proportion followed up by diagnostic group were compared, and found not to differ (Chi2 (2df) 
0.11, p 0.946).    
 
[Table 1 approximately here] 
 
3.2 Outcomes by baseline diagnosis 
Outcomes are described only for the core analytic sample (excluding those who died, moved abroad 
or were lost to follow-up as described by Morgan et al (2014). Table 2 describes the outcomes by 
baseline diagnosis for PMD, schizophrenia and bipolar/mania patients. The table shows that the only 
differences between PMD patients and bipolar patients were as follows: episodic course of illness 
which was less likely in PMD patients (OR 0.16, CI 0.06 to 0.40, p<0.01); GAF disability score at 
follow-up which was lower in PMD patients (indicating worse functioning, coefficient -10.85, CI -
18.66 to -3.04, p<0.01); and having been compulsorily admitted, which was far less likely to happen 
to PMD patients (OR 0.22, CI 0.08 to 0.59, p<0.01).  
 
There were more differences between PMD and schizophrenia patients. Compared with those with 
schizophrenia, PMD patients had a higher GAF symptom score at follow-up (indicating better 
functioning, coefficient 14.25, CI 8.13 to 20.37, p<0.01); were more likely to have an episodic course 
of illness (OR 3.02, CI 1.46 to 6.25, p<0.01);  had a higher GAF disability score at follow-up 
(coefficient 11.22, CI 4.78 to 17.65, p<0.01); were less likely to be employed for less than 25% of the 
follow-up (OR 0.34, CI 0.16 to 0.70, p<0.01); were more likely to be in a relationship over the follow-
up (OR 4.14, CI 1.95 to 8.78, p<0.01), were less likely to spend time in prison (OR 0.22, CI 0.05 to 
0.97, p<0.05); were less likely to be admitted compulsorily (OR 0.37, CI 0.18 to 0.76, p<0.01); and 
spent fewer inpatient days in hospital (coefficient -161.98, CI -272.25 to -51.70, p<0.01). 
 
[Table 2 approximately here] 
 
3.3 Outcomes by lifetime diagnosis 
Table 3 describes the outcomes by lifetime diagnosis for PMD, schizophrenia and bipolar/mania 
patients as well as comparisons between the PMD group and schizophrenia group, and the PMD and 
bipolar group. Data on diagnostic change are presented elsewhere (Heslin et al., 2015). In brief, of 
the 403 with baseline and lifetime diagnostic data, 15 changed from a baseline diagnosis of PMD to a 
follow-up diagnosis of schizophrenia, and seven changed from a baseline diagnosis of PMD to a 
lifetime diagnosis of bipolar disorder. Eight changed from schizophrenia to PMD, and two changed 
from bipolar to PMD. In terms of comparisons between PMD and BP patients, similarly to the 
baseline analyses, PMD patients had a lower GAF disability score at follow-up (indicating worse 
functioning, coefficient -10.16, CI -18.99 to -1.33, p<0.05); and were less likely to have been 
compulsorily admitted (OR 0.32, CI 0.12 to 0.84, p<0.05). GAF symptom score became significantly 
different between the groups with PMD patients having a lower score (and therefore worse 
symptoms, coefficient -8.77, CI -16.86 to -0.69, p<0.05). PMD patients were still less likely to have an 
episodic course of illness but this was not statistically significant (OR 0.44, CI 0.18 to 1.07, p 0.071). 
 
Comparisons between PMD and schizophrenia patients again revealed a large number of 
differences. Compared with those with schizophrenia, PMD patients had a higher GAF symptom 
score at follow-up (coefficient 11.40, CI 4.17 to 18.62, p<0.01); were more likely to have an episodic 
course of illness (OR 7.71, CI 3.51 to 16.92, p<0.01);  had a higher GAF disability score at follow-up 
(coefficient 12.78, CI 4.82 to 20.73, p<0.01); were less likely to be employed for less than 25% of the 
follow-up (OR 0.28, CI 0.12 to 0.65, p<0.01); were more likely to be in a relationship over the follow-
up (OR 4.79, CI 2.12 to 10.85, p<0.01); were less likely to be admitted compulsorily (OR 0.34, CI 0.15 
to 0.75, p<0.05); and spent fewer inpatient days in hospital (coefficient -243.05, CI -337.01 to -
149.09, p<0.01). The finding that PMD patients were much less likely to go to prison over the follow-
up was no longer evident (OR 0.33, CI 0.07-1.45, p>0.05); and there was new evidence that PMD 
patients were more likely to have close confidants (OR 9.21, CI 2.01 to 42.19, p<0.01). Additionally, 
there was some weak evidence (albeit not quite statistically significant at p < 0.05) that PMD 
patients were more likely to attempt suicide compared with schizophrenia patients (OR 2.31, CI 0.98 
to 5.42, p 0.055); and that PMD patients were more likely to self-harm (OR 2.34, CI 0.97 to 5.68, p 
0.060).  
 
[Table 3 approximately here] 
 
3.4 Posthoc analyses 
Following the finding that PMD patients had better social outcomes compared with schizophrenia 
but were more likely to self-harm or attempt suicide, post-hoc exploratory analyses were conducted 
to test whether those who self-harmed or attempted suicide had worse social outcomes than those 
who did not. There was some weak evidence (albeit not quite statistically significant at p < 0.05) 
based on the baseline diagnosis that those who attempted suicide were less likely to have a close 
confidant (OR 0.19, CI 0.03-1.20, p 0.077). Based on the lifetime diagnoses, there was some weak 
evidence (not quite statistically significant at p < 0.05) that PMD patients who self-harmed were 
more likely to work for more than 25% of the follow-up (OR 8.57, CI 0.83-89.04, p 0.072). 
  
4 Discussion 
Findings in this paper highlight that people with PMD have better social and service use outcomes 
compared with people with schizophrenia, but appear more likely to attempt suicide or self-harm. 
Outcomes for people with PMD are similar to those for people with bipolar/mania. Further, 
important differences between diagnostic groups were detected when accounting for diagnostic 
change. 
 
Despite addressing methodological limitations of previous work (using incidence sample while 
accounting for diagnostic change), these results are mostly consistent with previous research on 
outcomes in PMD patients compared to schizophrenia patients even though it is mostly based on 
non-incidence samples. This previous research suggests that compared to schizophrenia patients: 
PMD patients have a more episodic course of illness (92% versus 16%; Opjordsmoen, 1989), attempt 
suicide more (42% versus 27%; Radomsky et al., 1999) self-harm more (33% versus 18%, p<0.01; 
Crebbin et al., 2008), have better employment outcomes (Bromet et al., 1996; Opjordsmoen, 1989; 
Jager et al., 2005; Tsuang & Coryell, 1993; Sands & Harrow, 1999) have more stable relationships 
(Jager et al., 2005), and have better social contacts (Opjordsmoen, 1989; Tsuang & Coryell, 1993). 
Results from this study are consistent with these findings. In terms of service use, the majority of 
studies show that PMD patients have better inpatient outcomes compared with schizophrenia 
patients (less hospitalisations, lower scores on hospital outcomes, less continuous hospitalisations 
(Jager et al., 2005; Bromet et al., 1996; Tsuang & Coryell, 1993; Sands & Harrow, 1999; Craig et al., 
1997; Craig et al., 1997). However, some studies report worse inpatient outcomes in PMD patients 
(more patients admitted, more hospitalisations (Crebbin et al., 2008; Opjordsmoen, 1989; Stephens, 
1982). This study is consistent with the former as there were less inpatient days for the PMD 
patients and less compulsory admissions. 
 
Previous research on outcomes in PMD patients compared with patients with psychotic bipolar 
disorder have reported a range of non-significant differences or conflicting findings in a range of 
domains (Bromet et al., 1996; Welner et al., 1977; Aronson et al., 1987; Arsonson et al., 1988; 
Winokur et al., 1992). This study is consistent with these findings as there were minimum differences 
between the groups.  
 
4.1 Limitations 
As with all research, a number of limitations should be borne in mind when considering the findings. 
Firstly, although loss to follow-up was small considering the length of the study, this could have led 
to biased results, perhaps by either more severe or less severe patients being lost to follow-up. 
However, there were no differences in follow-up rates between the diagnostic groups. A further 
limitation is the simplification of outcomes. Relationship status was categorised into ‘in a 
relationship’ versus ‘single / divorced / separated’. This is an over simplification of a very complex 
phenomenon. It assumes that the quality of all relationships is equivalent and that the experience of 
being divorced is the same as being single or separated. Nonetheless, it provides useful information 
about whether a person has a partner as a potential form of social support. The recording and 
definitions of suicide attempts and self-harm are also relatively crude; further investigation is 
warranted of the nature and circumstances surrounding such events. Further, the cross-sectional 
nature of some of the data limits any causal links, e.g. with the finding that PMD patients had better 
social outcomes compared with schizophrenia but were more likely to self-harm or attempt suicide, 
both variables were obtained using the WHO Life Chart assessed at 10 years without accounting for 
or noting of temporality. Therefore, we cannot tell which preceded which. 
 
Finally, we cannot be sure whether lifetime diagnosis was influenced by factors beyond strict 
operational criteria (i.e. did outcomes influence what diagnosis was given). Lifetime diagnosis is 
often assumed to be more reliable and accurate than initial diagnosis as when patients present to 
services with a first episode of psychosis, the clinical picture can be confusing: patients may be 
experiencing psychotic symptoms, mood symptoms, confusion, distress, and it takes some time for 
the clinical diagnosis to become clearer. However, information on outcomes over time may well 
become (consciously or not) the basis for follow-up diagnosis. For example, people who self-harm 
and/or attempt suicide may be more likely to get a follow-up diagnosis of PMD, and less likely to get 
a follow-up diagnosis of schizophrenia. Further, as not all cases agreed to be interviewed at follow-
up, some diagnoses had to be made on the basis of clinical notes. This may have introduced some 
bias around what clinicians choose to record and omit. This information bias also applies to 
assessment of some of the outcomes (e.g. self-harm) which would only be known about had 
clinicians found out, and recorded these events in the notes. Although these are clearly problems, it 
is less clear how these limitations might be overcome in future research. 
 
4.2 Clinical implications 
Based on lifetime diagnoses, PMD patients are around twice as likely as schizophrenia patients to 
attempt suicide, with around a third (31%) of patients attempting suicide at some point within the 
first ten years following first episode of psychosis (although this needs to be viewed with caution 
given the small sample size and consequently imprecise estimates of effect size). This is compared to 
14.5% in a sample of depressed patients over 5 years (Holma et al, 2010). This highlights the need 
for clinicians to be extra vigilant of potential suicidal behaviour in PMD patients compared to 
schizophrenia patients, but also highlights the need to explore for the presence of psychotic 
symptoms in all depressive illness. However, PMD patients were hospitalised less and had 
comparatively good social outcomes. This contradiction is important for clinicians to bear in mind in 
any risk assessment. Further, we have identified an important subgroup of patients with a different 
emphasis of need. People with PMD are less likely to need help with improving social outcomes, but 
may need additional support to disclose and manage self-harm behaviour.  
 
4.3 Future research  
Although we have covered some key areas of outcome in this study (employment, social isolation (as 
indicated by relationship status and presence of a close confidant) and prison time), there are other 
important domains of outcome  – such as poverty and housing (Warner, 2008) - that are beyond the 
scope of the data presented here. These key areas also need to be investigated in people with PMD. 
Further, a better understanding of the incongruous findings of better social and service outcomes 
but worse self-harm and suicide is needed. 
 
 
 
  
References 
 
Amin S, Singh SP, Brewin J, Jones PB, Medley I. & Harrison G. Diagnostic stability of first-episode 
psychosis: Comparison of ICD-10 and DSM-III-R systems. British Journal of Psychiatry, 1999, 175, 
537-543. 
 
Aronson TA, Shukla S, & Hoff A. Continuation Therapy After ECT for Delusional Depression: A 
Naturalistic Study of Prophylactic Treatments and Relapse. Convulsive Therapy, 1987, 3, 251-259. 
 
AronsonTA, Shukla S, Hoff A, & Cook B. Proposed delusional depression subtypes: Preliminary 
evidence from a retrospective study of phenomenology and treatment course. Journal of Affective 
Disorders, 1988, 14, 69-74. 
 
Baldwin P, Browne D, Scully PJ, Quinn JF, Morgan MG, Kinsella A, Owens JM, Russell V, O’Callaghan 
E. & Waddington JL. Epidemiology of first-episode psychosis: Illustrating the challenges across 
diagnostic boundaries through the Cavan-Monaghan study at 8 years. Schizophrenia Bulletin, 2005, 
31, 624-638. 
 
Bromet EJ, Jandorf L, Fennig S, Lavelle J, Kovasznay B, Ram R, Tanenberg-Karant M. & Craig T. The 
Suffolk County Mental Health Project: Demographic, pre-morbid and clinical correlates of 6-month 
outcome. Psychological Medicine, 1996, 26, 953-962. 
 
Burns T, Creed F, Fahy T, Thompson S, Tyrer P, White I. Intensive versus standard case management 
for severe psychotic illness: a randomised trial. UK 700 Group. Lancet, 1999, 353, 2185–2189. 
 
Ciccone JR & Racy J. Psychotic depression and hallucinations. Comprehensive Psychiatry, 1975, 16, 
233-236. 
 
Ciompi L. Catamnestic long-term study on the course of life and aging of schizophrenics. 
Schizophrenia Bulletin, 1980, 6, 606-18. 
 
Cohen P, Cohen J. The clinician’s illusion. Archives of General Psychiatry, 1984, 41, 1178–1182. 
 
Craig TJ. et al. Is there an association between duration of untreated psychosis and 24- month 
clinical outcome in a first-admission series? American Journal of Psychiatry, 2000, 157, 60-66. 
 
Craig TJ et al. Diagnosis, treatment, and six-month outcome status in first-admission psychosis. 
Annals of Clinical Psychiatry, 1997, 9, 89-97. 
 
Crebbin K, Mitford E, Paxton R. & Turkington D. First-episode psychosis: An epidemiological survey 
comparing psychotic depression with schizophrenia. Journal of Affective Disorders, 2008, 105, 117-
124. 
 
DelBello MP, Carlson GA, Tohen M, Bromet EJ, Schwiers M. & Strakowski SM. Rates and Predictors of 
Developing a Manic or Hypomanic Episode 1 to 2 Years Following a First Hospitalization for Major 
Depression with Psychotic Features. Journal of Child and Adolescent Psychopharmacology, 2003, 13, 
173-185. 
 
Endicott J, Spitzer RL, Fleiss JL. & Cohen J. The Global Assessment Scale: a procedure for measuring 
overall severity of psychiatric disturbance. Archives of General Psychiatry, 1976,  33, 766–771. 
 
Harrison G, Hopper K, Craig T, Laska E, Siegel C, Wanderling J, Dube KC, Ganev K, Giel R, an der 
Heiden W, Holmberg SK, Janca A, Lee PW, Leon CA, Malhotra S, Marsella AJ, Nakane Y, Sartorius N, 
Shen Y, Skoda C, Thara R, Tsirkin SJ, Varma VK, Walsh D, Wiersma D. Recovery from psychotic illness: 
a 15- and 25-year international follow-up study. British Journal of Psychiatry, 2001, 178, 506–517. 
 
Heslin M, Lomas B, Lappin J, Donoghue K, Reininghaus UA, Onyejiaka A, Croudace T, Jones PB, 
Murray RM, Fearon P, Dazzan P, Morgan C, & Doody GA. Diagnostic change ten years after a first 
episode of psychosis: findings from ÆSOP-10. Psychological Medicine, 2015. 
 
Hill M, Crumlish N, Clarke M, Whitty P, Owens E, Renwick L, Browne S, Macklin EA, Kinsella A, Larkin 
C, Waddington JL & O'Callaghan E. Prospective relationship of duration of untreated psychosis to 
psychopathology and functional outcome over 12 years. Schizophrenia Research, 2012, 141, 215-21. 
 
Holma KM, Melartin TK, Haukka J, Holma IAK, Sokero TP, & Isometsä ET. Incidence and Predictors of 
Suicide Attempts in DSM–IV Major Depressive Disorder: A Five-Year Prospective Study. American 
Journal of Psychiatry, 2010, 167, 801–808. 
 
Jager,M., Bottlender,R., Strauss,A., & Moller,H.-J. Fifteen-year follow-up of Diagnostic and Statistical 
Manual of Mental Disorders, Fourth Edition depressive disorders: The prognostic significance of 
psychotic features. Comprehensive Psychiatry, 2005,  46, 322-327. 
 
Kielhorn JM & Graf von Schulenberg A. The health economics handbook. Adis International Limited: 
Chester, England, 2000. 
 
Kirkbride JB, Errazuriz A, Croudace TJ, Morgan C, Jackson D, Boydell J, Murray RM. & Jones PB. 
Incidence of schizophrenia and other psychoses in England, 1950-2009: A systematic review and 
meta-analyses. PLoS ONE, 2012, 7, e31660. 
 
Kirkbride JB, Fearon P, Morgan C, Dazzan P, Morgan K, Tarrant J, Lloyd T, Holloway J, Hutchinson G, 
Leff JP, Mallett RM, Harrison GL, Murray RM, & Jones PB. Heterogeneity in Incidence Rates of 
Schizophrenia and Other Psychotic Syndromes: Findings from the 3-center ÆSOP study. Archives of 
General Psychiatry, 2006, 63, (3) 250-258. 
 
Mallett R. Sociodemographic Schedule. London, 1997. 
 
Morgan C, Lappin J, Heslin M, Donoghue K, Lomas B, Reininghaus UA, Onyejiaka A, Croudace T, Jones 
PB, Murray RM, Fearon P, Doody GA, & Dazzan P. Reappraising the Long-term Course and Outcome 
of Psychotic Disorders: The ÆSOP-10 Study. Psychological Medicine, 2014, 44 (13), 2713-2726. 
 
Opjordsmoen S. Long-term course and outcome in unipolar affective and schizoaffective psychoses. 
Acta Psychiatrica Scandinavica, 1989, 79, 317-326. 
 
Radomsky E, Haas G, Mann J. & Sweeney J. Suicidal Behavior in Patients With Schizophrenia and 
Other Psychotic Disorders. American Journal of Psychiatry, 1999, 156, 1590-1595. 
 
Sands JR & Harrow M. Depression during the longitudinal course of schizophrenia. Schizophrenia 
Bulletin, 1999, 25, 157-171. 
 
Sartorius N, Gulbinat W, Harrison G, Laska E, Siegel C. Long-term follow-up of schizophrenia in 16 
countries. A description of the International Study of Schizophrenia conducted by the World Health 
Organization. Social Psychiatry and Psychiatric Epidemiology, 1996,  31, 249–258. 
 
Schimmelmann BG, Conus P, Edwards J, McGorry PD, & Lambert M. Diagnostic stability 18 months 
after treatment initiation for first-episode psychosis. Journal of Clinical Psychiatry, 2005, 66, 1239-
1246. 
 
StataCorp LP. STATA 10.1 for Windows. Texas, USA, StataCorp LP, 2009. 
 
Stephens,J.H. A comparison of nine systems to diagnose schizophrenia. Psychiatry Research, 1982, 6, 
127-143. 
 
Takei N, Persaud R, Woodruff P, Brockington I. & Murray RM. First episodes of psychosis in Afro-
Caribbean and White people. An 18-year follow-up population-based study. British Journal of 
Psychiatry, 1998, 172, 147-53. 
 
Tsuang D. & Coryell W. An 8-year follow-up of patients with DSM-III-R psychotic depression, 
schizoaffective disorder, and schizophrenia. American Journal of Psychiatry, 1993, 150, 1182-1188. 
 
Warner R. Social factors as a basis for treatment in Society and Psychosis (eds. Morgan C, McKenzie 
K. & Fearon P.) 163-178 (Cambridge University Press, Cambridge, 2008). 
 
Welner A, Croughan J, Fishman R. & Robins E. The group of schizoaffective and related psychoses: A 
follow-up study. Comprehensive Psychiatry, 1977, 18, 413-422. 
 
Whitty P, Clarke M, McTigue O, Browne S, Kamali M, Larkin C, & O’Callaghan E. Diagnostic Stability 
Four Years After a First Episode of Psychosis. Psychiatric Services, 2005, 56, 1084-1088. 
 
Winokur G, Black DW, & Nasrallah A. The schizoaffective continuum. 25-34, 1992.  
 
World Health Organisation. The ICD-10 Classification of Mental and Behavioural Disorders: 
Diagnostic criteria for research Geneva, World Health Organisation, 1993. 
 
World Health Organisation. SCAN V2 (Schedules for Clinical Assessment in Neuropsychiatry: Version 
2). Geneva, World Health Organisation, 1994. 
 
 
  
Tables 
 
 
Table 1: Baseline demographics of full sample and by diagnostic groups. 
 PMD (n72) Schizophrenia (n218) Bipolar (n70) Overall sample (n360) 
 Median (IQR) Median (IQR) Median (IQR) Median (IQR) 
Age 32.50 (25-41) 29.00 (22-35) 27.00 (23-33) 29.00 (23-36) 
 N (%) N (%) N (%) N (%) 
Study centre: 
London  
Nottingham  
 
35 (48.6) 
37 (51.4) 
 
151 (69.3) 
67 (30.7) 
 
44 (62.9) 
26 (37.1) 
 
230 (63.9) 
130 (36.1) 
Gender: 
Male 
Female 
 
36 (50.0) 
36 (50.0) 
 
140 (64.2) 
78 (35.8) 
 
33 (47.1) 
37 (52.9) 
 
209 (58.1) 
151 (41.9) 
Ethnicity: 
White British 
African-Caribbean 
Black African 
White Other 
Asian 
Other (all) 
 
37 (51.4) 
8 (11.1) 
7 (9.7) 
4 (5.6) 
7 (9.7) 
9 (12.5) 
 
81 (37.2) 
61 (28.0) 
33 (15.1) 
22 (10.9) 
10 (4.6) 
11 (5.1) 
 
27 (38.6) 
14 (20.0) 
11 (15.7) 
4 (5.7) 
6 (8.6) 
8 (11.4) 
 
145 (40.3) 
30 (8.3) 
83 (23.1) 
51 (14.2) 
23 (6.4) 
28 (7.8) 
Place of birth: 
UK 
Non-UK 
 
50 (69.4) 
22 (30.6) 
 
148 (69.8) 
64 (30.2) 
 
53 (76.8) 
16 (23.2) 
 
251 (71.1) 
102 (28.9) 
IQR = Interquartile range. 
 
 
 
  
Table 2: Comparison of outcomes by baseline diagnosis 
 Outcomes Comparisons 
 PMD SZ BP PMD vs. SZ PMD vs. BP  
Clinical outcomes 
 Median (IQR) Median (IQR) Median (IQR) Beta coefficient (CI) Beta coefficient (CI) 
Global Assessment of functioning – 
symptoms 
71.5 
(58.5-80.5) 
55 
(42-65) 
79  
(65-87) 
14.25 
(8.13 to 20.37)** 
-4.80 
(-12.27 to 2.68) 
 n (%) n (%) n (%) OR (CI) OR (CI) 
Course of illness 
Not episodic 
(continuous/neither) 
Episodic 
 
31 (63.3) 
 
18 (36.7) 
 
125 (83.9) 
 
24 (16.1) 
 
10 (21.7) 
 
36 (78.3) 
 
- 
3.02 
(1.46 to 6.25)** 
 
- 
0.16 
(0.06 to 0.40)** 
Attempted suicide 
No 
Yes 
 
35 (79.6) 
9 (20.5) 
 
119 (83.8) 
23 (16.2) 
 
36 (83.7) 
7 (16.3) 
 
- 
1.33 (0.56 to 3.14) 
 
- 
1.32 (0.44 to 3.94) 
Self-harmed  
No 
Yes 
 
37 (80.4) 
9 (19.6) 
 
121 (86.4) 
19 (13.6) 
 
38 (88.4) 
5 (11.6) 
 
- 
1.55 (0.65 to 3.71) 
 
- 
1.85 (0.57 to 6.04) 
Social outcomes 
 Median (IQR) Median (IQR) Median (IQR) Beta coefficient (CI) Beta coefficient (CI) 
Global Assessment of functioning – 
disability 
62 (50-75) 47 (40-60) 80 (64-86) 11.22  
(4.78 to 17.65)** 
-10.85  
(-18.66 to -3.04)** 
 n (%) n (%) n (%) OR (CI) OR (CI) 
Employment status: 
Employed 25-100% 
Employed 0-25% 
 
20 (50.0) 
20 (50.0) 
 
34 (25.2) 
101 (74.8) 
 
17 (47.2) 
19 (52.8) 
 
- 
0.34 (0.16 to 0.70)** 
 
- 
0.89 (0.36 to 2.20) 
Main relationship status: 
Single/divorced/separated 
In a relationship 
 
19 (48.7) 
20 (51.3) 
 
110 (79.7) 
28 (20.3) 
 
23 (56.1) 
18 (43.9) 
 
- 
4.14 (1.95 to 8.78)** 
 
- 
1.35 (0.56 to 3.24) 
Close confidant: 
No 
Yes 
 
8 (28.6) 
20 (71.4) 
 
37 (46.3) 
43 (53.8) 
 
6 (25.0) 
18 (75.0) 
 
- 
2.15 (0.85 to 5.45) 
 
- 
0.83  (0.24 to 2.87) 
Went to prison: 
No 
Yes 
 
43 (95.6) 
2 (4.4) 
 
113 (82.5) 
24 (17.5) 
 
40 (93.0) 
3 (7.0) 
 
- 
0.22 (0.05 to 0.97)* 
 
- 
0.62 (0.10 to 3.91) 
Service use outcomes 
 Median (IQR) Median (IQR) Median (IQR) Beta coefficient (CI) Beta coefficient (CI) 
Total number of days hospitalised 63.5 (19.5-
181.6) 
107 (25-275) 79 (24-182) -161.98  
(-272.25 to -51.70)** 
-74.44  
(-235.21 to 86.34) 
 n (%) n (%) n (%) OR (CI) OR (CI) 
Ever admitted compulsorily: 
No 
Yes 
 
23 (54.8) 
19 (45.2) 
 
37 (30.8) 
83 (69.2) 
 
8 (21.1) 
30 (79.0) 
 
- 
0.37 (0.18 to 0.76)** 
 
- 
0.22 (0.08 to 0.59)** 
*p<0.05; **p<0.01; OR = odds ratio; CI = 95% confidence interval; IQR = Interquartile range; PMD = Psychotic Major Depression; SZ = Schizophrenia; BP = Bipolar disorder. 
 
 
 
 
  
Table 3: Comparison of outcomes by lifetime diagnosis 
 Outcomes Comparisons 
 PMD SZ BP PMD vs. SZ PMD vs. BP  
Clinical outcomes 
 Median (IQR) Median (IQR) Median (IQR) Beta coefficient (CI) Beta coefficient (CI) 
Global Assessment of functioning – 
symptoms 
65 (57-79) 55 (41-65) 78 (65-87) 11.40 
(4.17 to 18.62)** 
-8.77  
(-16.86 to -0.69)* 
 n (%) n (%) n (%) OR (CI) OR (CI) 
Course of illness 
Not episodic 
(continuous/neither) 
Episodic 
 
 
16 (44.4) 
20 (55.6) 
 
 
148 (86.1) 
24 (14.0) 
 
 
14 (25.9) 
40 (74.1) 
 
- 
7.71 
(3.51 to 16.92)** 
 
- 
0.44 
(0.18 to 1.07) 
Attempted suicide 
No 
Yes 
 
22 (68.8) 
10 (31.3) 
 
137 (83.5) 
27 (16.5) 
 
42 (82.4) 
9 (17.7) 
 
- 
2.31 (0.98 to 5.42)  
 
- 
2.12 (0.75 to 5.99) 
Self-harmed  
No 
Yes 
 
26 (74.3) 
9 (25.7) 
 
142 (87.1) 
21 (12.9) 
 
42 (85.7) 
7 (14.3)) 
 
- 
2.34 (0.97 to 5.68)  
 
- 
2.08 (0.69 to 6.25) 
Social outcomes 
 Median (IQR) Median (IQR) Median (IQR) Beta coefficient (CI) Beta coefficient (CI) 
Global Assessment of functioning – 
disability 
65 (51-80) 48 (40-60) 81.5 (63.5-85.5) 12.78 (4.82 to 20.73)** -10.16 (-18.99 to -1.33)* 
 n (%) n (%) n (%) OR (CI) OR (CI) 
Employment status: 
Employed 25-100% 
Employed 0-25% 
 
14 (52.9) 
13 (48.2) 
 
36 (23.1) 
120 (76.9) 
 
23 (54.8) 
19 (45.2) 
 
- 
0.28 (0.12 to 0.65)** 
 
- 
1.12 (0.43 to 2.96) 
Main relationship status: 
Single/divorced/separated 
In a relationship 
 
14 (46.7) 
16 (53.3) 
 
130 (80.8) 
31 (19.3) 
 
22 (47.8) 
24 (52.2) 
 
- 
4.79 (2.12 to 10.85)** 
 
- 
1.05 (0.42 to 2.63) 
Close confidant: 
No 
Yes 
 
2 (10.0) 
18 (90.0) 
 
43 (50.6) 
42 (49.4) 
 
9 (30.0) 
21 (70.0) 
 
- 
9.21 (2.01 to 42.19)** 
 
- 
3.86 (0.74 to 20.21) 
Went to prison: 
No 
Yes 
 
31 (93.9) 
2 (6.1) 
 
132 (83.5) 
26 (16.5) 
 
46 (95.8) 
2 (4.2) 
 
- 
0.33 (0.07 to 1.45) 
 
- 
1.48 (0.20 to 11.10) 
Service use outcomes 
 Median (IQR) Median (IQR) Median (IQR) Beta coefficient (CI) Beta coefficient (CI) 
Total number of days hospitalised 22 (0-99) 128 (48-371) 73 (28-165) -243.05  
(-337.01 to -149.09)** 
-54.72  
(-119.59 to 10.15) 
 N (%) N (%) N (%) OR (CI) OR (CI) 
Ever admitted compulsorily: 
No 
Yes 
 
16 (51.6) 
15 (48.4) 
 
37 (26.4) 
103 (73.6) 
 
12 (25.5) 
35 (74.5) 
 
- 
0.34 (0.15 to 0.75)* 
 
- 
0.32 (0.12 to 0.84)* 
*p<0.05; **p<0.01; OR = odds ratio; CI = 95% confidence interval; IQR = Interquartile range; PMD = Psychotic Major Depression; SZ = Schizophrenia; BP = Bipolar disorder. 
 
 
 
 
 
 
 
 
 
